Cargando…

Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?

Detalles Bibliográficos
Autores principales: Bril, Fernando, Al Diffalha, Sameer, Dean, Mark, Fettig, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Association for the Study of the Liver. Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056822/
https://www.ncbi.nlm.nih.gov/pubmed/33862041
http://dx.doi.org/10.1016/j.jhep.2021.04.003
_version_ 1783680728328830976
author Bril, Fernando
Al Diffalha, Sameer
Dean, Mark
Fettig, David M.
author_facet Bril, Fernando
Al Diffalha, Sameer
Dean, Mark
Fettig, David M.
author_sort Bril, Fernando
collection PubMed
description
format Online
Article
Text
id pubmed-8056822
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Association for the Study of the Liver. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-80568222021-04-20 Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty? Bril, Fernando Al Diffalha, Sameer Dean, Mark Fettig, David M. J Hepatol Letter to the Editor European Association for the Study of the Liver. Published by Elsevier B.V. 2021-07 2021-04-20 /pmc/articles/PMC8056822/ /pubmed/33862041 http://dx.doi.org/10.1016/j.jhep.2021.04.003 Text en © 2021 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Letter to the Editor
Bril, Fernando
Al Diffalha, Sameer
Dean, Mark
Fettig, David M.
Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?
title Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?
title_full Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?
title_fullStr Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?
title_full_unstemmed Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?
title_short Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?
title_sort autoimmune hepatitis developing after coronavirus disease 2019 (covid-19) vaccine: causality or casualty?
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8056822/
https://www.ncbi.nlm.nih.gov/pubmed/33862041
http://dx.doi.org/10.1016/j.jhep.2021.04.003
work_keys_str_mv AT brilfernando autoimmunehepatitisdevelopingaftercoronavirusdisease2019covid19vaccinecausalityorcasualty
AT aldiffalhasameer autoimmunehepatitisdevelopingaftercoronavirusdisease2019covid19vaccinecausalityorcasualty
AT deanmark autoimmunehepatitisdevelopingaftercoronavirusdisease2019covid19vaccinecausalityorcasualty
AT fettigdavidm autoimmunehepatitisdevelopingaftercoronavirusdisease2019covid19vaccinecausalityorcasualty